Добавление психотерапии к антидепрессантам при депрессивных и тревожных расстройствах: мета-анализ
Всемирная психиатрия. №1 2014
Добавление психотерапии к антидепрессантам при депрессивных и тревожных расстройствах: мета-анализ
Pim Cuijpers1-3, Marit Sijbrandij1,2, Sander L. Koole1,2, Gerhard Andersson4,5, Aartjan T. Beekman2,6, Charles F. Reynolds III7
1Department of Clinical Psychology, VU University Amsterdam, The Netherlands (Нидерланды); 2EMGO Institute for Health and Care Research, VU University and VU University Medical Center Amsterdam, The Netherlands (Нидерланды); 3Leuphana University, Lunebrug, Germany (Германия); 4Department of Behavioural Sciences and Learning, Swedish Institute for Disability Research, University of Linkoping, Sweden (Швеция); 5Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institute, Stockholm, Sweden (Швеция); 6Department of Psychiatry, VU University Medical Center Amsterdam, The Netherlands; 7department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (США)
Стр. 56-66
1458 просмотров
Опубликовано: 11 февраля 2014
Аннотация / Abstract
Перевод: Сюняков Т.С.
Авторами проведен мета-анализ рандомизированных исследований, направленный на сравнение размеров эффектов терапии антидепрессантами и комбинированного применения фармако- и психотерапиии у взрослых пациентов с диагнозами депрессивных или тревожных расстройств. Критериям включения в мета-анализ в общей сложности соответствовало 52 исследования (n=3623): 32 исследования депрессивных расстройств и 21 исследование тревожных расстройств (одно исследование включало больных и депрессивными, и тревожными расстройствами). Общее различие между фармакотерапией и комбинированная терапией по показателю величины эффекта g Хеджеса составило 0,43 (95% ДИ: 0,31-0,56), что указывает на умеренный размер эффекта и клинически значимое различие в пользу комбинированной терапии и соотносится с показателем NNT (число пациентов, которых необходимо пролечить, для того, чтобы один дополнительный пациент получил выгоду от терапии) 4,20. Получены достаточные свидетельства того, что комбинированная терапия превосходит по эффективности фармакотерапию при большом депрессивном, паническом и обсессивно-компульсивном (ОКР) расстройствах. Размер эффекта комбинированной терапии по сравнению с плацебо оказался в два раза выше, чем размер эффекта фармакотерапии по сравнению с плацебо, что подчеркивает клиническое преимущество применения комбинированной терапии. Полученные результаты также свидетельствуют о том, что эффекты фармакотерапии и психотерапии по большей части являются независимыми друг от друга и примерно в одинаковой мере участвуют в реализации эффекта комбинированной терапии. Мы пришли к выводу, что при большом депрессивном расстройстве, паническом расстройстве и ОКР комбинированная терапия представляется более эффективной, чем простая терапия одними антидепрессантами. Данные эффекты сохраняют свою силу и значимость даже через 2 года после окончания лечения. Терапия одними психотропными препаратами может не являться оптимальным подходом для лечения распространенн...
Перевод: Сюняков Т.С.
Авторами проведен мета-анализ рандомизированных исследований, направленный на сравнение размеров эффектов терапии антидепрессантами и комбинированного применения фармако- и психотерапиии у взрослых пациентов с диагнозами депрессивных или тревожных расстройств. Критериям включения в мета-анализ в общей сложности соответствовало 52 исследования (n=3623): 32 исследования депрессивных расстройств и 21 исследование тревожных расстройств (одно исследование включало больных и депрессивными, и тревожными расстройствами). Общее различие между фармакотерапией и комбинированная терапией по показателю величины эффекта g Хеджеса составило 0,43 (95% ДИ: 0,31-0,56), что указывает на умеренный размер эффекта и клинически значимое различие в пользу комбинированной терапии и соотносится с показателем NNT (Ñ...
Материал для специалистов
Полный текст статьи доступен только зарегистрированным пользователям.
Вход / Регистрация- 1. Kessler RC, Berglund P, Demler O et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105.
- 2. Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62: 593-602.
- 3. Ustun TB, Ayuso-Mateos JL, Chatterji S et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184: 386-92.
- 4. Saarni SI, Suvisaari J, Sintonen H et al. Impact of psychiatric disorders on health-related quality of life: general population survey. Br J Psychiatry 2007;190:326-32.
- 5. Berto P, D’Ilario D, Ruffo P et al. Депрессия: cost-of-illness studies in the international literature: a review. J Ment Health Policy Econ 2000;3:3-10.
- 6. Greenberg PE, Birnbaum HG. The economic burden of depression in the US: societal and patient perspectives. Exp Opin Phar- macother 2005;6:369-76.
- 7. Smit F, Cuijpers P, Oostenbrink J et al. Excess costs of common mental disorders: population based cohort study. J Ment Health Policy Econ 2006;9:193-200.
- 8. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
- 9. National Institute for Health and Clinical Excellence (NICE). Depression; the treatment and management of depression in adults. Holborn: NICE, 2009.
- 10. Bauer M, Bschor T, Pfennig A et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 2007;8:67-104.
- 11. Bandelow B, Sher L, Bunevicius R et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 2012;16:77-84.
- 12. Cuijpers P, Sijbrandij M, Koole SL et al. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. (World Psychiatry 2013;12:137-48)
- 13. Cuijpers P, Dekker J, Hollon SD et al. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry 2009;70:1219-29.
- 14. Cuijpers P, van Straten A, Warmerdam L et al. Psychological treatment versus combined treatment of depression: a meta-analysis. Depress Anx 2009;26:279-88.
- 15. de Maat SM, Dekker J, Schoevers RA et al. Relative efficacy of psychotherapy and combined therapy in the treatment of depression: a meta-analysis. Eur Psychiatry 2007;22:1-8.
- 16. Olfson M, Marcus SC. National trends in outpatient psychotherapy. Am J Psychiatry 2010;167:1456-63.
- 17. Marcus SC, Olfson M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry 2010;67:1265-73.
- 18. Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews 2007 (1): CD004364.
- 19. Hofmann SG, Sawyer AT, Korte KJ et al. Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. Int J Cogn Ther 2009; 2:160-75.
- 20. Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions. Version 5.0.1. Oxford: Cochrane Collaboration, 2008.
- 21. Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego: Academic Press, 1985.
- 22. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006;59:990-6.
- 23. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
- 24. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
- 25. Ioannidis JPA, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007;335:914-6.
- 26. Orsini N, Higgins J, Bottai M et al. Heterogi: Stata module to quantify heterogeneity in a meta-analysis. Boston: Boston College Department of Economics, 2005.
- 27. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63.
- 28. Azhar MZ. Comparison of Fluvoxamine alone, Fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan - implications for management by family doctors. Med J Malaysia 2000;55:402-8.
- 29. Barlow DH, Gorman JM, Shear MK et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000;283:2529-36.
- 30. Bellack AS, Hersen M, Himmelhoch J. Social skills training compared with pharmacotherapy and psychotherapy in the treatment of unipolar depression. Am J Psychiatry 1981;138:1562-67.
- 31. Bellino S, Zizza M, Camilla R et al. Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Am J Psychiatry 2006;51:253-60.
- 32. Berger P, Sachs G, Amering M et al. Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder. J Affect Disord 2004;80:75-8.
- 33. Blackburn IM, Bishop S, Glen AI et al. The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. Br J Psychiatry 1981;139:181-9.
- 34. Blanco C, Heimberg RG, Schneier FR et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010;67:286-95.
- 35. Blom MB, Spinhoven P, Hoffman T et al. Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression. J Affect Disord 2007;104: 119-26.
- 36. Blomhoff S, Haug TT, Hellstrom K et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001;179:23-30.
- 37. Browne G, Steiner M, Roberts J et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord 2002;68:317-30.
- 38. Burnand Y, Andreoli A, Kolatte E et al. Psychodynamic psychotherapy and clomipramine in the treatment of major depression. Psychiatr Serv 2002;53:585-90.
- 39. Crits-Christoph P, Newman MG, Rickels K et al. Combined medication and cognitive therapy for generalized anxiety disorder. J Anxiety Disord 2011;25:1087-94.
- 40. Davidson JRT, Foa EB, Huppert JD et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004;61:1005-13.
- 41. de Jonghe F, Kool S, van Aalst G et al. Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord 2001;64:217-29.
- 42. de Mello MF, Myczcowisk LM, Menezes PR. A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder. J Psychother Pract Res 2001;10:117-23.
- 43. Dozois DJA, Bieling PJ, Patelis-Siotis I et al. Changes in self-schema structure in cognitive therapy for major depressive disorder: a randomized clinical trial. J Consult Clin Psychol 2009;77:1078-88.
- 44. Finkenzeller W, Zobel I, Rietz S et al. Interpersonal psychotherapy and pharmacotherapy for post-stroke depression. Feasibility and effectiveness. Nervenarzt 2009;80:805-12.
- 45. Foa EB, Liebowitz MR, Kozak MJ et al. Randomized, placebo- controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005;162:151-61.
- 46. Hautzinger M, de Jong-Meyer R, Treiber R et al. Wirksamkeit Kognitiever Verhaltenstherapie, Pharmacotherapie und deren Kombination bei nicht-endogenen, unipolaren Depressionen. Zeitschr Klin Psychol 1996;25:130-45.
- 47. Hellerstein DJ, Little SAS, Samstag LW et al. Adding group psychotherapy to medication treatment in dysthymia: a randomized prospective pilot study. J Psychother Pract Res 2001;10:93-103.
- 48. Hollon SD, DeRubeis RJ, Evans MD et al. Cognitive therapy and pharmacotherapy for depression: singly and in combination. Arch Gen Psychiatry 1992;49:774-81.
- 49. Hsiao FH, Jow GM, Lai YM et al. The long-term effects of psychotherapy added to pharmacotherapy on morning to evening diurnal cortisol patterns in outpatients with major depression. Psychother Psychosom 2011;80:166-72.
- 50. Keller MB, McCullough JP, Klein DN et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-70.
- 51. King ALS, Valenca AM, de Melo-Neto VL et al. Efficacy of a specific model for cognitive-behavioral therapy among panic disorder patients with agoraphobia: a randomized clinical trial. Sao Paulo Med J 2011;129:325-34.
- 52. Koszycki D, Taljaard M, Segal Z et al. A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder. Psychol Med 2011;41:373-83.
- 53. Lesperance F, Frasure-Smith N, Koszycki D et al. Effects of cita- lopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007;297:367-79.
- 54. Loerch B, Graf-Morgenstern M, Hautzinger M et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry 1999;174:
- 205-12.
- 55. Lynch TR, Morse JQ, Mendelson T et al. Dialectical behavior therapy for depressed older adults: a randomized pilot study. Am J Geriatr 2003;11:33-45.
- 56. Macaskill ND, Macaskill A. Rational-emotive therapy plus pharmacotherapy vs. pharmacotherapy alone in the treatment of high cognitive dysfunction depression. Cogn Ther Res 1996;20: 575-92.
- 57. Maina G, Rosso G, Rigardetto S et al. No effect of adding brief dynamic therapy to pharmacotherapy in the treatment of obsessive-compulsive disorder with concurrent major depression. Psychother Psychosom 2010;79:
- 295-302.
- 58. Markowitz JC, Kocsis JH, Bleiberg KL et al. A comparative trial of psychotherapy and pharmacotherapy for “pure” dysthymic patients. J Affect Disord 2005;89:167-75.
- 59. Misri S, Reebye P, Corral M et al. The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. J Clin Psychiatry 2004;65:1236-41.
- 60. Mitchell PH, Veith RC, Becker KJ et al. Brief psychosocial- behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: living well with stroke: randomized, controlled trial. Stroke 2009;40:3073-8.
- 61. Murphy GE, Simons AD, Wetzel RD et al. Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression. Arch Gen Psychiatry 1984;41:33-41.
- 62. Mynors-Wallis LM, Gath DH, Day A et al. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ 2000;320:26-30.
- 63. Naeem F, Waheed W, Gobbi M et al. Preliminary evaluation of culturally sensitive CBT for depression in Pakistan: findings from Developing Culturally-sensitive CBT Project (DCCP). Behav Cogn Psychother 2011;39:165-73.
- 64. Otto MW, Hinton D, Korbly NB et al. Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive- behavior therapy vs sertraline alone. Behav Res Ther 2003;41:1271-6.
- 65. Prasko J, Dockery C, Horacek J et al. Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuroendocrinol Lett 2006;27:473-81.
- 66. Ravindran AV, Anisman H, Merali Z et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. Am J Psychiatry 1999;156:1608-17.
- 67. Reynolds CF 3rd, Miller MD, Pasternak RE et al. Treatment of bereavement-related major depressive episodes in later life: a controlled study of acute and continuation treatment with nortriptyline and interpersonal psychotherapy. Am J Psychiatry 1999;156: 202-8.
- 68. Rothbaum BO, Cahill SP, Foa EB et al. Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress 2006;19:625-38.
- 69. Shamsaei F, Rahimi A, Zarabian MK et al. Efficacy of pharmacotherapy and cognitive therapy, alone and in combination in major depressive disorder. Hong Kong J Psychiatry 2008;18:76-80.
- 70. Shareh H, Gharraee B, Atef-Vahid MK et al. Metacognitive Therapy (MCT), fluvoxamine, and combined treatment in improving obsessive-compulsive, depressive and anxiety symptoms in patients with Obsessive-Compulsive Disorder (OCD). Iran J Psychiatry Behav Sci 2010;4:17-25.
- 71. Sharp DM, Power KG, Simpson RJ et al. Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia. J Anxiety Dis 1996;10:219-42.
- 72. Sirey JA, Bruce ML, Alexopoulos GS. The Treatment Initiation Program: an intervention to improve depression outcomes in older adults. Am J Psychiatry 2005;162:184-6.
- 73. Spinhoven P, Onstein EJ, Klinkhamer RA et al. Panic management, trazodone and a combination of both in the treatment of panic disorder. Clin Psychol Psychother 1996;3:
- 86-92.
- 74. Tenneij NH, Megen HJ, Denys DAJP et al. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry 2005;66: 1169-75.
- 75. Thompson LW, Coon DW, Gallagher-Thompson D et al. Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression. Am J Geriatr Psychiatry 2001;9:
- 225-40.
- 76. van Apeldoorn FJ, van Hout WJPJ, Huisman M et al. Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia. Acta Psychiatr Scand 2008;17:
- 260-70.
- 77. Weissman MM, Prusoff BA, Dimascio A et al. The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. Am J Psychiatry 1979;136:555-8.
- 78. Wiborg IM, Dahl AA. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch Gen Psychiatry 1996;53: 689-94.
- 79. Wiles NJ, Hollinghurst S, Mason V et al. A randomized controlled trial of cognitive behavioural therapy as an adjunct to pharmacotherapy in primary care based patients with treatment resistant depression: a pilot study. Behav Cogn Psychother 2008;36:21-33.
- 80. Katz R, Shaw BF, Vallis TM et al. The assessment of severity and symptom patterns in depression. In: Beckham EE, Leber WR (eds). Handbook of depression, 2nd ed. New York: Guilford, 1995:61-85.
- 81. Turner EH, Matthews AM, Linardatos E et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
- 82. Cuijpers P, Smit F, Bohlmeijer et al. Is the efficacy of cognitive behaviour therapy and other psychological treatments for adult depression overestimated? A meta-analytic study of publication bias. Br J Psychiatry 2010;196:173-8.
- 83. Friedman MA, Detweiler-Bedell JB, Leventhal HE et al. Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder. Clin Psychol Sci Pract 2004;11:47-68.
- 84. Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin Psychol Sci Pract 2005;12:72-86.